Efficacy Study of CPC634 (CriPec® Docetaxel) in Platinum Resistant Ovarian Cancer (CINOVA)

• Sponsor: Cristal Therapeutics
• Information provided by (Responsible Party): Cristal Therapeutics

Study Description

Brief Summary:

The purpose of this study is to determine whether CPC634 (CriPec® docetaxel) is effective in the treatment of patients with advanced epithelial ovarian cancer who are resistant to prior platinum-based chemotherapy

.

Condition or disease	Intervention/treatment	Phase
Cancer; Ovarian Cancer	Drug: CPC634 (CriPec® docetaxel)	Phase 2

Detailed Description:

This Phase IIa exploratory 2-stage trial will assess the efficacy, safety and tolerability of CPC634 (CriPec® docetaxel) administered IV, Q3W to 27 subjects (13 in Stage 1 and 14 in Stage 2) with ovarian cancer that is resistant to prior platinum-based therapy. Subjects will be treated continuously every 21 days at 60 mg/m2, which is the RP2D of CPC634 (CriPec® docetaxel) that was determined in the Phase I CT-CL01, until disease progression, unacceptable toxicity, or discontinuation for any other reason.

Study Design

Layout table for study information

Study Type :	Interventional (Clinical Trial)
Estimated Enrollment :	27 participants
Intervention Model:	Single Group Assignment
Masking:	None (Open Label)
Primary Purpose:	Treatment
Official Title:	A Phase Ila Exploratory 2-stage Design Study of CPC634 (CriPec® Docetaxel) Monotherapy in Subjects With Platinum Resistant Ovarian Cancer.
Actual Study Start Date :	October 1, 2018
Estimated Primary Completion Date :	March 31, 2020
Estimated Study Completion Date :	May 31, 2020

Arms and Interventions

Arm	Intervention/treatment
Experimental: CPC634 (CriPec® docetaxel); CPC634 (CriPec® docetaxel) administered intra-venously every 21 days at 60 mg/m2	Drug: CPC634 (CriPec® docetaxel); Docetaxel containing CriPec® nanoparticles

Outcome Measures

Primary Outcome Measures :

1. Objective Response Rate (ORR) [ Time Frame: At the end of Cycle 6 (each cycle is 21 days) ]
   To determine the Objective Response Rate (ORR) as assessed by Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1 of CPC634 (CriPec® docetaxel) monotherapy in subjects with ovarian cancer who are resistant to prior platinum-based therapy.

Secondary Outcome Measures :

1. Incidence of Treatment-Emergent Adverse Events (safety and tolerability) [ Time Frame: At the end of Cycle 6 (each cycle is 21 days) ]
   To evaluate the incidence of Treatment-Emergent Adverse Events (safety and tolerability) of CPC634 (CriPec® docetaxel) according to NCI-CTCAE criteria (version 5.0)
2. Progression free survival [ Time Frame: After 6 months ]
   Progression free survival (PFS) at 6 months based on RECIST version 1.1. and combined assessment using Gynecological Cancer Intergroup (GCIG) definitions for CA-125
3. GCIG CA-125 response criteria [ Time Frame: At the end of Cycle 6 (each cycle is 21 days) ]
   GCIG CA-125 response criteria defined as at least a 50% reduction in CA-125 levels from a pretreatment sample confirmed and maintained for at least 28 days
4. Duration of response (DOR) [ Time Frame: At the end of Cycle 6 (each cycle is 21 days) ]
   Duration of response (DOR) based on RECIST version 1.1 and combined assessment using GCIG definitions for CA-125
5. Time to progression (TTP) [ Time Frame: After 6 months ]
   Time from treatment assignment to time of progressive disease per RECIST version 1.1.
6. Disease control rate (DCR) [ Time Frame: At the end of Cycle 6 (each cycle is 21 days) ]
   Disease control rate (DCR) will be determined based on the percentage of subjects who have achieved complete response (CR), partial response (PR) and stable disease (SD) with treatment of CriPec® docetaxel

Eligibility Criteria

Layout table for eligibility information

Ages Eligible for Study:	18 Years and older (Adult, Older Adult)
Sexes Eligible for Study:	Female
Accepts Healthy Volunteers:	No

Criteria

Inclusion Criteria:

1. Age 8 years.
2. Histologically or cytologically confirmed diagnosis of epithelial ovarian, fallopian or peritoneal cancer.
3. Platinum-resistant recurrent epithelial ovarian cancer (defined as progression within 6 months after last platinum dose). There is no limit to the number of previous treatment lines, but a maximum of 3 lines of therapy for platinum-resistant disease, of which one could have been taxane- based.
4. Measurable disease according to RECIST version 1.1. Only CA-125 progression without any clinical or radiological progression is not allowed.
5. Performance status (WHO scale/ECOG) 1.
6. Estimated life expectancy of at least 12 weeks.
7. Toxicities incurred as a result of previous anti-cancer therapy (radiation therapy, chemotherapy, or surgery) must be resolved to ≤ Grade 2 (as defined by NCI- CTCAE version 5.0).
8. ANC ≥ 1.5 x 109/L; platelets ≥100 x 109/L; hemoglobin ≥ 5.58 mmol/L (≥ 9.00 g/dL)
9. Creatinine ≤ 1.75 x Upper Limit of Normal (ULN) and estimated creatinine clearance ≥ 30 mL/min according to Cockcroft-Gault formula; Serum albumin levels > 25g/L.
10. Serum bilirubin ≤ 1.5 x ULN except for subjects with Will Gilbert's syndrome; alkaline phosphatase, ASAT and ALAT ≤ 2.5 x ULN, unless related to liver metastases, in which case ≤ 5 x ULN is allowed.
11. Written informed consent according to local guidelines.

Exclusion Criteria:

1. Subjects with platinum-refractory disease. Refractory disease is defined by subjects who progressed during the preceding treatment or within 4 weeks after last dose of platinum containing therapy.
2. Less than four weeks since the last treatment with other anti-cancer therapies, (i.e. endocrine therapy, immunotherapy, radiotherapy, chemotherapy, etc.); less than eight weeks for cranial radiotherapy, and less than six weeks for nitrosoureas and mitomycin C prior to first study treatment.
3. Current or recent (within 28 days of first study treatment) treatment with another investigational drug or participation in another investigational study.
4. Active or symptomatic brain metastases. Subjects must be on a stable or decreasing dose of corticosteroids and/or have no requirement for anticonvulsants for five days prior to Cycle 1 day1 (C1D1).
5. Current malignancies other than epithelial ovarian, fallopian or peritoneal cancer, with exception of adequately treated cone-biopsied in situ carcinoma of the cervix uteri and basal or squamous cell carcinoma of the skin.
6. Major surgical procedure (including open biopsy, excluding central line IV and portacath) within 28 days prior to the first study treatment, or anticipation of the need for major surgery during the course of the study treatment.
7. Uncontrolled hypertension (systolic > 150 mm Hg and/or diastolic > 100mm Hg).
8. Grade ≥ 2 motor or sensory neuropathy symptoms (as defined by CTCAE version 5.0).
9. Known hypersensitivity to any of the study drugs or excipients or taxanes.
10. Any skin toxicity in the medical history of the subject of Grade ≥ 2 associated with impaired skin integrity (skin toxicity defined as any form of rash, HFS, skin ulceration, toxic epidermal necrolysis, eczema) or any skin toxicity for which systemic treatment was needed.
11. Clinically significant (i.e. active) cardiovascular disease defined as stroke, transient ischemic attack (TIA) or myocardial infarction within ≤ 6 months prior to first trial treatment.
12. Subjects, who are pregnant or breastfeeding. Serum pregnancy test to be performed within 7 days prior to study treatment start in subjects of childbearing potential.
13. Absence of highly effective method of contraception as of C1D1 in female subjects of childbearing potential (defined as < 2 years after last menstruation and not surgically sterile).
14. Known hypersensitivity to dexamethasone or any other reason that would make the subject not eligible to receive dexamethasone.
15. Evidence of any other medical conditions (such as psychiatric illness, infectious diseases, drug or alcohol abuse, physical examination or laboratory findings) that may interfere with the planned treatment, affect subject compliance or place the subject at high risk from treatment- related complications.

Contacts and Locations

Contacts

Layout table for location contacts

Contact: Rob Hanssen, PhD	+31 43 3885868	rob.hanssen@cristaltherapeutics.com
Contact: Axel Mescheder, MD,PhD	+31 43 3885868	axel.mescheder@cristaltherapeutics.com

Locations

Layout table for location information

Belgium
Universitaire Ziekenhuizen Leuven	Recruiting
Leuven, Belgium, B3000
Contact: Ignace Vergote, MD,PhD +32 16 34 51 28 ignace.vergote@uzleuven.be
United Kingdom
UCL Cancer Institute	Not yet recruiting
London, United Kingdom, W1T 4TJ
Contact: Jonathan Ledermann, MD,PhD +44 2076799898 j.ledermann@ucl.ac.uk

Sponsors and Collaborators

Cristal Therapeutics

Investigators

Layout table for investigator information

Principal Investigator:	Jonathan Ledermann, MD,PhD	UCL Cancer Institute, London, UK

More Information

Layout table for additonal information

Responsible Party:	Cristal Therapeutics
ClinicalTrials.gov Identifier:	NCT03742713 History of Changes
Other Study ID Numbers:	CT-CL02
First Posted:	November 15, 2018
Last Update Posted:	November 15, 2018
Last Verified:	November 2018
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD:	No

Layout table for additional information

Studies a U.S. FDA-regulated Drug Product:		No
Studies a U.S. FDA-regulated Device Product:		No

Additional relevant MeSH terms:

Layout table for MeSH terms

Ovarian Neoplasms; Carcinoma, Ovarian Epithelial; Endocrine Gland Neoplasms; Neoplasms by Site; Neoplasms; Ovarian Diseases; Adnexal Diseases; Genital Diseases, Female; Genital Neoplasms, Female; Urogenital Neoplasms; Endocrine System Diseases	Gonadal Disorders; Carcinoma; Neoplasms, Glandular and Epithelial; Neoplasms by Histologic Type; Docetaxel; Antineoplastic Agents; Tubulin Modulators; Antimitotic Agents; Mitosis Modulators; Molecular Mechanisms of Pharmacological Action